Compare ELVA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVA | STRO |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Canada | United States |
| Employees | N/A | 131 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.5M | 338.9M |
| IPO Year | 2021 | N/A |
| Metric | ELVA | STRO |
|---|---|---|
| Price | $8.99 | $34.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $14.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 350.7K | 223.8K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.68 | N/A |
| Revenue Next Year | $51.48 | N/A |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $0.67 |
| 52 Week High | $11.88 | $36.00 |
| Indicator | ELVA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 72.00 |
| Support Level | $7.10 | $0.78 |
| Resistance Level | $11.67 | N/A |
| Average True Range (ATR) | 0.62 | 2.61 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 40.43 | 87.24 |
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.